Vita Life SciencesASX:VLS 94 FCF Margin % is 20.93% as of Dec. 2025, which is 140% above its 10-year median of 8.73. GuruFocus rates ASX:VLS with a GF Score™ of 94/100 and a GF Value™ of A$2.47 (Fairly Valued). The stock has 1 warning sign investors should review. Among 958 Drug Manufacturers companies, Vita Life Sciences ranks better than 84.66% on this metric.
The historical rank and industry rank for Vita Life Sciences's FCF Margin % or its related term are showing as below:
ASX:VLS'
s FCF Margin % Range Over the Past 10 Years
Min: 3.41 Med: 8.73 Max: 17
Current: 17
During the past 13 years, the highest FCF Margin % of Vita Life Sciences was 17.00%. The lowest was 3.41%. And the median was 8.73%.
ASX:VLS's FCF Margin % is ranked better than 84.66% of 958
companies
in the Drug Manufacturers industry
Industry Median: 2.51
vs ASX:VLS: 17.00
Vita Life Sciences FCF Margin % Related Terms
Vita Life Sciences FCF Margin % Historical Data
* Premium members only.
The historical data trend for Vita Life Sciences's FCF Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Vita Life Sciences's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Vita Life Sciences FCF Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Vita Life Sciences's FCF Margin % distribution charts can be found below:
* The bar in red indicates where Vita Life Sciences's FCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Vita Life Sciences (ASX:VLS) has a FCF Margin % of 20.93% as of Dec. 2025. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Vita Life Sciences and its competitors. This is 140% above median its historical median of 8.73. Over the past decade, Vita Life Sciences' FCF Margin % has ranged from 3.41 to 17.00. According to the industry distribution chart, Vita Life Sciences ranks #147 out of 958 companies in the Drug Manufacturers industry, placing it in the top 15.3%.
Is Vita Life Sciences' FCF Margin % too high?
Vita Life Sciences' current FCF Margin % of 20.93% is 140% above median its 10-year median of 8.73. Over the past 10 years, this metric has ranged from a low of 3.41 to a high of 17.00. The Drug Manufacturers industry median FCF Margin % is 2.51. Vita Life Sciences' value of 20.93% is 733.9% above this industry median. Based on the distribution chart, Vita Life Sciences ranks #147 out of 958 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Vita Life Sciences has a GF Score™ of 94/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Vita Life Sciences' FCF Margin % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Vita Life Sciences ranks #147 out of 958 companies for FCF Margin %. This places Vita Life Sciences in the top 15% of its industry — outperforming the majority of peers. The industry median FCF Margin % is 2.51. Vita Life Sciences' value of 20.93% is 733.9% above this benchmark. Historically, Vita Life Sciences' own FCF Margin % has ranged from 3.41 to 17.00 over the past decade. While the company's 10-year median is 8.73 vs. the industry median of 2.51, Vita Life Sciences has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Drug Manufacturers company?
The median FCF Margin % among Drug Manufacturers companies is 2.51, based on 958 companies in the industry. Companies in the top quartile (top 25%) have a FCF Margin % significantly above this median, while those in the bottom quartile fall well below. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Vita Life Sciences's current FCF Margin % of 20.93% is 733.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Vita Life Sciences and its competitors. For the Drug Manufacturers industry, the median FCF Margin % is 2.51 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Vita Life Sciences's current FCF Margin % is 20.93%, which is 140% above median its own 10-year median of 8.73. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vita Life Sciences stock overvalued right now?
Based on GuruFocus' analysis, Vita Life Sciences (ASX:VLS) is currently considered Fairly Valued. The stock's GF Value™ is A$2.47, compared to a current price of A$2.50 — trading 1.2% above its estimated fair value. The current FCF Margin % is 20.93%, which is 140% above median its 10-year median of 8.73 and 733.9% above the Drug Manufacturers industry median of 2.51. Vita Life Sciences' overall GF Score™ is 94/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For Vita Life Sciences (ASX:VLS), the current FCF Margin % is 20.93% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Vita Life Sciences (ASX:VLS) Overvalued in 2026?
Based on GuruFocus' analysis, Vita Life Sciences stock appears to be overvalued.
The current stock price of A$2.50 is trading 1.2% above its estimated GF Value™ of A$2.47.
GuruFocus considers Vita Life Sciences to be Fairly Valued.
Key valuation signals for ASX:VLS:
FCF Margin %: 20.93% (140% above median its 10-year median of 8.73)
GF Value™: A$2.47 vs. price of A$2.50 (1.2% above fair value)
Industry Position: 733.9% above the Drug Manufacturers median (#147 of 958)
No single metric tells the full story. See the ASX:VLS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Vita Life Sciences Ltd is an Australian-based pharmaceutical and healthcare company involved in formulating, packaging, selling, and distributing vitamins and supplements. It produces a wide range of premium supplements, vitamins, minerals, herbs, and superfoods catered to all age categories and health conditions. The company markets its products through pharmacies and health food stores under the VitaHealth, VitaScience, and Herbs of Gold brands throughout the Asia-Pacific region. Vita Life Sciences has two operating segments: VMS Operational, which generates maximum revenue, and VMS Investments. Geographically, the Group generates maximum revenue from Malaysia and Singapore, and the rest from Australia, and China and Vietnam.
94GF Score
Get the complete analysis for ASX:VLS
FCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:VLS has been successfully added to your 
